Jamil Khurram 4

What Happened
Jamil Khurram, Chief Medical Officer of Galectin Therapeutics (GALT), exercised 7,557 option-derived shares and sold the same 7,557 shares on June 23, 2026. The exercise reported shows a cash cost of $1.23 per share (total $9,295). The shares were sold in open-market transactions at a weighted-average price of $3.14 per share (total proceeds ~$23,729), resulting in gross proceeds roughly $14,434 greater than the exercise cost. A related derivative disposition is reported at $0.00, reflecting the conversion/exercise of the options.

Key Details

• Transaction date: June 23, 2026.
• Exercise: 7,557 shares exercised at $1.23 each — total cost $9,295. (Code M)
• Sale: 7,557 shares sold at a weighted-average price of $3.14 — total proceeds ~$23,729. (Code S)
• Sale prices ranged from $3.10 to $3.17 across multiple trades (Footnote F2).
• Sale executed under a Rule 10b5‑1 trading plan adopted Feb 2, 2026 (Footnote F1).
• Vesting note: options vest in tranches of 16,250 on 6/30/2025, 12/31/2025, 6/30/2026 and 12/31/2026 (Footnote F3).
• Shares owned after the transactions: not specified in the provided filing.
• Filing timeliness: no late filing flag indicated in the provided data.

Context
Because the exercise and sale occurred the same day, this functions like a cashless exercise (options converted to shares and then sold), producing net proceeds after covering the exercise cost. The sale was conducted under a pre-established 10b5‑1 plan, which is commonly used to automate insider sales and avoid questions about timing; such sales are typically considered routine and not a directional signal by themselves.